Citadel Advisors
AGIO icon

Citadel Advisors’s Agios Pharmaceuticals AGIO Stock Holding History

Citadel Advisors’s Portfolio AGIO Stock Details AGIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.22M Buy
65,700
+15,500
+31% +$439K ﹤0.01% 5868
2025
Q4 		$1.37M Sell
50,200
-24,100
-32% -$846K ﹤0.01% 6727
2025
Q3 		$2.98M Buy
74,300
+41,000
+123% +$1.54M ﹤0.01% 5321
2025
Q2 		$1.11M Buy
33,300
+7,800
+31% +$236K ﹤0.01% 6872
2025
Q1 		$747K Buy
25,500
+16,100
+171% +$534K ﹤0.01% 7604
2024
Q4 		$309K Sell
9,400
-3,300
-26% -$155K ﹤0.01% 9597
2024
Q3 		$564K Sell
12,700
-2,500
-16% -$114K ﹤0.01% 8005
2024
Q2 		$655K Sell
15,200
-15,400
-50% -$556K ﹤0.01% 7474
2024
Q1 		$895K Buy
30,600
+19,400
+173% +$519K ﹤0.01% 7145
2023
Q4 		$249K Sell
11,200
-4,000
-26% -$89.6K ﹤0.01% 9527
2023
Q3 		$376K Buy
15,200
+400
+3% +$10.6K ﹤0.01% 8684
2023
Q2 		$419K Buy
14,800
+10,600
+252% +$264K ﹤0.01% 8323
2023
Q1 		$96.5K Sell
4,200
-27,600
-87% -$733K ﹤0.01% 11322
2022
Q4 		$893K Sell
31,800
-35,200
-53% -$992K ﹤0.01% 7026
2022
Q3 		$1.9M Buy
67,000
+42,300
+171% +$1.13M ﹤0.01% 5689
2022
Q2 		$548K Sell
24,700
-7,200
-23% -$163K ﹤0.01% 8440
2022
Q1 		$929K Buy
31,900
+14,100
+79% +$431K ﹤0.01% 7875
2021
Q4 		$585K Buy
17,800
+9,100
+105% +$366K ﹤0.01% 9298
2021
Q3 		$402K Sell
8,700
-12,900
-60% -$623K ﹤0.01% 10397
2021
Q2 		$1.19M Sell
21,600
-9,200
-30% -$514K ﹤0.01% 7888
2021
Q1 		$1.59M Buy
30,800
+3,600
+13% +$178K ﹤0.01% 6957
2020
Q4 		$1.18M Buy
27,200
+19,600
+258% +$775K ﹤0.01% 6450
2020
Q3 		$266K Sell
7,600
-6,600
-46% -$289K ﹤0.01% 8339
2020
Q2 		$759K Sell
14,200
-19,300
-58% -$894K ﹤0.01% 6339
2020
Q1 		$1.19M Sell
33,500
-4,600
-12% -$213K ﹤0.01% 5024
2019
Q4 		$1.82M Buy
38,100
+25,500
+202% +$964K ﹤0.01% 4565
2019
Q3 		$408K Sell
12,600
-69,400
-85% -$2.87M ﹤0.01% 7092
2019
Q2 		$4.09M Buy
82,000
+54,400
+197% +$2.91M ﹤0.01% 3396
2019
Q1 		$1.86M Sell
27,600
-11,700
-30% -$681K ﹤0.01% 4581
2018
Q4 		$1.81M Buy
39,300
+5,200
+15% +$321K ﹤0.01% 4297
2018
Q3 		$2.63M Buy
34,100
+300
+0.9% +$24.1K ﹤0.01% 3945
2018
Q2 		$2.85M Buy
33,800
+15,500
+85% +$1.35M ﹤0.01% 3562
2018
Q1 		$1.5M Buy
18,300
+13,200
+259% +$1.02M ﹤0.01% 4183
2017
Q4 		$292K Sell
5,100
-5,800
-53% -$365K ﹤0.01% 6506
2017
Q3 		$728K Buy
10,900
+600
+6% +$36K ﹤0.01% 4790
2017
Q2 		$530K Sell
10,300
-1,500
-13% -$76.7K ﹤0.01% 5027
2017
Q1 		$689K Sell
11,800
-8,100
-41% -$388K ﹤0.01% 4523
2016
Q4 		$830K Sell
19,900
-2,100
-10% -$110K ﹤0.01% 4117
2016
Q3 		$1.16M Sell
22,000
-9,700
-31% -$422K ﹤0.01% 3634
2016
Q2 		$1.33M Buy
31,700
+8,000
+34% +$395K ﹤0.01% 3212
2016
Q1 		$962K Buy
23,700
+1,600
+7% +$68.4K ﹤0.01% 3540
2015
Q4 		$1.44M Sell
22,100
-700
-3% -$45.9K ﹤0.01% 3142
2015
Q3 		$1.61M Sell
22,800
-7,200
-24% -$704K ﹤0.01% 3218
2015
Q2 		$3.33M Sell
30,000
-15,000
-33% -$1.62M ﹤0.01% 2473
2015
Q1 		$4.24M Sell
45,000
-24,900
-36% -$2.79M ﹤0.01% 2195
2014
Q4 		$7.83M Buy
69,900
+58,000
+487% +$5.18M 0.01% 1589
2014
Q3 		$730K Buy
+11,900
New +$513K ﹤0.01% 4122

Other funds holding AGIO

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
EAM
Erste Asset Management Vienna, Austria $10.8B AUM 38.54% 1-Year Est. Return
BNP Paribas Asset Management
BNP Paribas Asset Management Paris, France $86.1B AUM 29.11% 1-Year Est. Return

Citadel Advisors's AGIO Position: Q1 2026 in Review

Citadel Advisors reduced its Agios Pharmaceuticals (AGIO) stake by 54% in Q1 2026, selling an estimated $20.7M and leaving 619,613 shares worth $21M. The position accounts for ﹤0.01% of the portfolio, ranked #2286.

Citadel Advisors first reported a position in AGIO in Q2 2014 and has held it in 42 quarters since. The position peaked at $47.1M in Q4 2024. 232 funds tracked by Wall St. Rank hold AGIO as of Q1 2026.

  • Citadel Advisors held 619,613 shares of Agios Pharmaceuticals worth $21M as of Q1 2026.
  • Citadel Advisors sold 729,355 Agios Pharmaceuticals shares in Q1 2026, an estimated $20.7M.
  • Agios Pharmaceuticals made up ﹤0.01% of Citadel Advisors's portfolio in Q1 2026, its #2286 holding.
  • Citadel Advisors first reported a position in Agios Pharmaceuticals in Q2 2014 and has held it in 42 quarters since.
  • Citadel Advisors's Agios Pharmaceuticals position peaked at $47.1M in Q4 2024.
  • 232 funds tracked by Wall St. Rank held Agios Pharmaceuticals as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.